Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
NCT00018057 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3500
Last updated 2026-05-22
Summary
Study Description:
This study examines relations between neurocognitive and clinical features of pediatric anxiety disorders. The study uses neuro-cognitive tasks, functional magnetic resonance imaging (fMRI), as well as magneto- and electro-encephalography (M/EEG). Patients will be studied over one year, before and after receiving either one of two standard-of-care treatments: cognitive behavioral therapy (CBT) or fluoxetine, a serotonin reuptake inhibitor (SSRI). Healthy comparisons will be studied at comparable time points.
Primary Objectives:
To compare healthy youth and symptomatic, medication-free pediatric patients studied prior to receipt of treatment. The study seeks to detect relations between clinical features of anxiety disorders at baseline and a wide range of neurocognitive features associated with attention, memory, and response to motivational stimuli.
Secondary Objectives:
1. To document relations between baseline neurocognitive features and response to Cognitive Behavioral Therapy (CBT) or fluoxetine, as defined by the Pediatric Anxiety Rating Scale (PARS) and Clinical Global Improvement (CGI) Scale.
2. To document relations between post-treatment changes in neurocognitive features and anxiety symptoms on the PARS following treatment with Cognitive Behavioral Therapy (CBT) or fluoxetine.
3. To document relations among broad arrays of clinical, cognitive, and neural measures
Primary Endpoints:
Indices of percent-signal change in hypothesized brain regions, comprising amygdala, striatum, and prefrontal cortex (PFC) for each fMRI and MEG paradigm.
Secondary Endpoints:
1. Treatment-response as defined by a continuous measure, the Pediatric Anxiety Rating Scale score (PARS), and a categorial measure, the Clinical Global Improvement (CGI) score.
2. Levels of symptoms and behaviors evoked by tasks that engage attention, memory, and elicit responses to motivational stimuli.
...
Conditions
Interventions
- BEHAVIORAL
-
Attention Bias Modification Training
The intervention is computer-based. The active and control treatments have two components. In one component of the active intervention, subjects are asked to indicate the identity of a letter that appears behind a neutral face, opposite from an angry face. In another component of the active intervention, subjects are asked to identify numbers that are hidden within a puzzle, in locations distal from angry faces. In both components of the active intervention, subjects implicitly learn to shift their attention away from angry faces. This is because the faces are systematically arranged to be far removed from letters and numbers that need to be identified. The control arm of the intervention involves similar components. However, unlike in the intervention arm, angry faces appear in various locations near letters and numbers. Therefore, attention is not shaped in the control arm. This intervention requires five minutes per session and is administered before weekly psychotherapy sessions.
- DRUG
-
Fluoxetine
Randomized assignment.
- BEHAVIORAL
-
Cognitive Behavioral Therapy
Sponsors & Collaborators
-
National Institute of Mental Health (NIMH)
lead NIH
Principal Investigators
-
Daniel S Pine, M.D. · National Institute of Mental Health (NIMH)
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 8 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2001-10-02
- Primary Completion
- 2029-01-01
- Completion
- 2029-01-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Cognitive Training for Mood and Anxiety Disorders
NCT02256566 ·Status: COMPLETED ·Phase: NA
-
Sleep, Mood, and Behavior Study
NCT00787397 ·Status: COMPLETED ·Phase: NA
-
Neural Correlates of Cognitive Rehabilitation in Post-Traumatic Stress Disorder (PTSD)
NCT00928941 ·Status: TERMINATED ·Phase: NA
-
Computerized Intervention Targeting the Error-Related Negativity and Balance N1 in Anxious Children
NCT05503017 ·Status: COMPLETED ·Phase: NA
-
Targeting the ERN Computerized Intervention Targeting the Error-related Negativity in Young Children
NCT04571814 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Stress & Self-Control Costs
NCT05795179 ·Status: RECRUITING ·Phase: NA
-
Brain Imaging of Psychotherapy for Posttraumatic Stress Disorder (PTSD)
NCT01507948 ·Status: COMPLETED ·Phase: NA
-
Neurofeedback of Amygdala Activity for Post-traumatic Stress Disorder
NCT03574974 ·Status: TERMINATED ·Phase: NA
-
Mindfulness-based Cognitive Therapy for Patients With Functional Disorders
NCT00497185 ·Status: COMPLETED ·Phase: NA
-
fMRI in Posttraumatic Stress Disorder (PTSD) During Working Memory Updating
NCT00288314 ·Status: COMPLETED
-
Fluoxetine vs EMDR to Treat Post-Traumatic Stress Disorder (PTSD)
NCT00000379 ·Status: COMPLETED ·Phase: PHASE3
-
fMRI Predictors of Treatment Response in Posttraumatic Stress Disorder (PTSD)
NCT01576510 ·Status: COMPLETED ·Phase: NA
-
A fMRI Study of the Treatment of Danish Veterans With PTSD With Prolonged Exposure Therapy
NCT02519296 ·Status: UNKNOWN ·Phase: NA
-
CPT-fMRI Study for PTSD
NCT03229915 ·Status: COMPLETED ·Phase: NA
-
3MDR to Treat PTSD With mTBI (3MDR)
NCT03796936 ·Status: COMPLETED ·Phase: PHASE2
-
The Role of Expectations in the Development of Intrusive Memories
NCT03950869 ·Status: COMPLETED ·Phase: NA
-
Trauma Informed Treatment Algorithms for Novel Outcomes
NCT04304378 ·Status: COMPLETED ·Phase: NA
-
Cognitive Behavioral Therapy With Parental Involvement for Treating Children With Anxiety Disorders
NCT00620958 ·Status: COMPLETED ·Phase: NA
-
Enhancing Transdiagnostic Mechanisms of Cognitive Dyscontrol
NCT04912089 ·Status: COMPLETED ·Phase: NA
-
Neural Correlates of Early Intervention for Posttraumatic Stress Disorder (PTSD)
NCT00665678 ·Status: TERMINATED ·Phase: PHASE4
-
Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD)
NCT03874793 ·Status: COMPLETED ·Phase: NA
-
Norepinephrine Transporter Availability in PTSD
NCT01799837 ·Status: COMPLETED ·Phase: PHASE1
-
Substance P Antagonist in the Treatment of Posttraumatic Stress Disorder
NCT00383786 ·Status: COMPLETED ·Phase: PHASE2
-
Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs
NCT00560781 ·Status: COMPLETED ·Phase: NA
-
A Working Memory Training to Decrease Rumination in Depressed and Anxious Individuals
NCT02119975 ·Status: COMPLETED ·Phase: NA